Navigation Links
Boca Pharmacal Receives FDA Approval for Hydrocodone Bitartrate and Acetaminophen Tablets
Date:1/27/2011

CORAL SPRINGS, Fla., Jan. 27, 2011 /PRNewswire/ -- Boca Pharmacal, Inc. announced today that the U.S. Food and Drug Administration (FDA) approval and commercial launch of Hydrocodone Bitartrate and Acetaminophen (5mg/300mg, 7.5mg/300mg and 10mg/300mg) Boca's generic version of Victory Pharma's Xodol®. Hydrocodone Bitartrate and Acetaminophen is indicated for the relief of moderate to moderately severe pain

(Logo: http://photos.prnewswire.com/prnh/20110127/FL37887LOGO)

ABOUT BOCA PHARMACAL

Boca Pharmacal is a privately held pharmaceutical research and development company with full marketing and distribution.  Founded in 1998 the company has focused on ability to offer lower volume items that may have been overlooked by some of the larger generic companies.  Boca markets over 30 products and has a robust pipeline of lower cost generic alternatives.


'/>"/>
SOURCE Boca Pharmacal, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Womens Health Market
2. Mission Pharmacal Launches New Vitamin B6-Rich Prescription Prenatal Vitamin, CitraNatal(R) B-Calm
3. Mission Pharmacal Launches CitraNatal(R) Assure Prescription Prenatal Vitamin
4. China Sky One Medical Receives Medical Industry Awards
5. Lakewood-Amedex Inc. Receives Notice of Allowance on Three US Patent Applications Relating to Treatment of Hemolytic Uremic Syndrome
6. Varian Medical Systems Security and Inspection Products Group Receives Largest Single Order for IntellX Systems
7. Crestwood Technology Group Receives Silver Boeing Performance Excellence Award
8. HeartWare Receives Third Patient Allotment From FDA - Authorizing 94 Additional Patients - Under Continued Access Protocol for Pivotal U.S. Bridge-to-Transplant Clinical Trial
9. Mylans Matrix Receives Approval for Generic Version of Protonix® Delayed-release Tablets
10. Aribex CEO Receives Utah Governors Medal
11. Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for Lamivudine and Zidovudine Tablets, 30 mg/60 mg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... and LONDON , Nov. 25, ... AstraZeneca (NYSE: AZN ) today announced that AMAGINE-2 ... doses of brodalumab in more than 1,800 patients with moderate-to-severe ... Stelara ® (ustekinumab) and placebo at week 12. Brodalumab ... analysis group were each shown to be superior to Stelara ...
(Date:11/26/2014)... 26, 2014 China Nepstar Chain Drugstore Ltd. (NYSE: ... leading retail drugstore chain in China based on the ... financial results for the third quarter ended September 30, 2014. ... , Same store sales increased by 8.1% compared ... increased by 8.1% to RMB738.3 million (US$120.3 million) compared to ...
(Date:11/24/2014)... 2014 Luoxis Diagnostics, Inc., a subsidiary ... announced the presentation of three clinical and preclinical ... broadly applicable and robust research tool capable of ... response to injury, illness, or stress.  In all ... Luoxis, academic and pharmaceutical research partners, RedoxSYS was ...
Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 11Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 2Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 3Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 4Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 5
(Date:11/26/2014)... (PRWEB) November 26, 2014 Call 866-997-4948 ... requirements or email the details on sales(at)researchmoz(dot)us , ... and drug discovery market 2014" with deep study of ... the result of high blood sugar. The global glucose ... linked to the growing number of diabetics in the ...
(Date:11/26/2014)... 2014 Louisiana Back Institute, leaders ... in minimally invasive spine surgery, announces today the ... rapidly growing provider network of orthopedic spine surgeons ... with the network’s continuing success providing the most ... residents who are suffering from orthopedic spine conditions ...
(Date:11/26/2014)... 2014 (HealthDay News) -- Youngsters who enter puberty early ... suggests. Early puberty was linked with a number ... and high anxiety levels, according to the researchers. Early ... conflict with family and peers, and having friends who ... Although the study found an association between early ...
(Date:11/26/2014)... News) -- Exposure to peanut protein in household dust ... with the skin condition eczema, a new study reveals. ... United States are allergic to peanuts. And severe eczema ... peanut allergy, the researchers noted. The new study ... The researchers examined the amount of peanut protein the ...
(Date:11/24/2014)... Recently, Fecbek.com ( http://www.fecbek.com ), a leading online shopping mall ... history of the Black Friday to its fans worldwide. ... is the Black Friday! It is a shopping day popular ... However, not everyone knows the history of the Special Friday. ... day. , The fourth Friday in November is the date ...
Breaking Medicine News(10 mins):Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 3Health News:Louisiana Back Institute Welcomes Dr. K. Samer Shamieh into Medical Provider Network 2Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2Health News:Infants With Eczema May Be More Prone to Peanut Allergy: Study 2
... ... Health , ... (PRWEB) October 11, 2009 – The YWCA’s Week Without Violence kicks off today, acting as ... need for trained social workers throughout the world. Those interested becoming community support workers can ...
... - Mentalympians(TM) announced today, on this World Mental Health ... based in Australia, Canada, New Zealand, Scotland and the ... found on www.mentalympians.org . , Mentalympians has been ... operated through a network of mental health consumer groups. ...
... ... MAN (renewman.com), the first male hormone treatment program in the U.S., continues to ... symptoms, including andropause. A common condition among men ages 35 and older, reNEW ... doctor that can test, diagnose and treat hormone deficiencies through safe, self-administered treatments. ...
... with mental, neurological, and substance use (MNS) disorders in low ... the mental health "treatment gap." This week PLoS ... helping to close the gap. The series coincides with ... Mental Health, a collaborative initiative of the London School of ...
... InfoLogix, Inc. (Nasdaq: IFLG ), a leading ... and commercial industries, today announced that it has retained ... based in West Conshohocken, PA to assist InfoLogix in ... negotiates financing transactions at virtually every level of the ...
... (MIS), best known for regulating in utero sexual differentiation in ... according to a new study published online October 9 in ... associated with breast cancer risk, Joanne F. Dorgan, Ph.D., MPH, ... conducted a prospective case-control study of 309 participants who were ...
Cached Medicine News:Health News:YWCA's Week Without Violence Oct. 11-17 a Reminder That Community Support Workers Remain in High Demand 2Health News:World-first mental health media initiative announces inaugural Advisory Group 2Health News:Locate a Male Menopause Physician with reNEW MAN 2Health News:Locate a Male Menopause Physician with reNEW MAN 3Health News:Locate a Male Menopause Physician with reNEW MAN 4Health News:How should mental, neurological and substance use disorders be treated where resources are scarce? 2Health News:InfoLogix Announces News Related to its Recent Corporate Development Initiatives 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: